Soligenix (NASDAQ:SNGX) Issues Earnings Results

Soligenix (NASDAQ:SNGX) posted its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04, Zacks reports.

Soligenix Stock Up 3.5%

NASDAQ SNGX opened at $0.39 on Friday. Soligenix has a 52 week low of $0.28 and a 52 week high of $6.23. The stock’s 50-day moving average price is $0.41 and its 200-day moving average price is $0.81. The company has a market capitalization of $5.81 million, a P/E ratio of -0.23 and a beta of 1.93.

Institutional Investors Weigh In On Soligenix

Several large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in Soligenix in the 4th quarter worth about $37,000. Jane Street Group LLC bought a new position in shares of Soligenix during the fourth quarter valued at approximately $51,000. StoneX Group Inc. purchased a new stake in shares of Soligenix during the 4th quarter valued at $50,000. Geode Capital Management LLC lifted its position in Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 37,811 shares during the period. Finally, Armistice Capital LLC purchased a new position in shares of Soligenix during the third quarter worth $821,000. 3.60% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.